Tamtam Try Tamtam free
BrightSpring Health Services logo

BrightSpring Health Services account plan

Diverse healthcare services provider

At a glance

BrightSpring Health Services is a US home and community-based pharmacy and provider services platform: $12.9 billion FY2025 revenue.

BrightSpring Health Services, headquartered in Louisville, Kentucky, delivers complementary pharmacy and provider services to complex Senior and Specialty patients, largely funded by Medicare, Medicaid and commercial insurance, in home and community settings. It operates in all 50 states, Puerto Rico and Canada and serves approximately 500,000 patients daily through approximately 12,700 clinical providers and pharmacists (Q3 2026). FY2025 revenue grew 28.2% to $12.9 billion, Adjusted EBITDA rose 34.2% to $617.6 million and net income from continuing operations was $104.8 million; it had over 23,500 full-time equivalent employees at December 31, 2025. The company is listed and KKR remains a significant shareholder; Jon Rousseau is Chairman, President and CEO.

Business units

Strategic priorities

Specialty and infusion growth
Win limited distribution drug launches (19 year-to-date in 2026) and expand acute and chronic infusion at home and in suites.
Home-based primary care and value-based care
BrightSpring was selected for the REACH ACO Medicare program from January 1 and aims within 5 to 10 years to become a national brand for primary care in the community.
Integrated care
Deliver multiple pharmacy and provider services to the same patients, today approximately 10,000, using home-based primary care, transitional care and the Clinical (Nursing) Hub.
Volume, efficiency and accretive M&A
The CEO's playbook combines sales investment, Lean Sigma, technology and AI projects, with tuck-in acquisitions in home health, hospice, rehab, primary care and infusion.
Deleveraging and cash generation
Leverage fell to 1.79x at September 30, 2026 and management expects at least $700 million of operating cash flow in 2026.

Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue grew 26.4% to $4,213.2 million and Adjusted EBITDA 42.0% to $227.8 million; net income from continuing operations was $100.8 million and Adjusted EPS $0.54. Pharmacy Solutions revenue rose 25.8% to $3,732.4 million with segment EBITDA of $202.0 million, and Provider Services revenue 31.0% to $480.8 million, of which $76.1 million came from the Amedisys and LHC branches. The company raised full-year 2026 guidance to revenue of $15,900 million to $16,125 million and Adjusted EBITDA of $850 million to $860 million, and reiterated at least 15% to 20% organic Adjusted EBITDA growth for 2027.

Investments and deals

Community Living divestiture
The I/DD Community Living business was sold to National Mentor Holdings for $835.0 million, closing on March 30, 2026; proceeds helped repay $300.0 million of term debt.
Amedisys and LHC branches
110 home health and hospice branches in 18 states bought from Amedisys and UnitedHealth Group for $246.4 million in December 2025; expected to add approximately $35 million of Adjusted EBITDA in 2026.
Technology and AI
New EMR and ERP systems, a cloud data lake and BI platform, robotic process automation and AI-assisted recruiting; AI projects target documentation, medication review, HR and hiring, with returns expected more fully in 2027.
Continuous improvement
PMO-led continuous improvement delivered approximately $84.7 million of annual savings in 2025, reinvested in wages, quality, technology and growth.
Refinancing and buybacks
A new $2,214.9 million Tranche B-6 term loan was set up on May 28, 2026, and $120.0 million of shares were repurchased in 2026.

Challenges and risks

Inflation Reduction Act impact
Approximately $200 million of IRA impact in specialty and infusion and approximately $175 million in home and community pharmacy were expected for 2026.
Government reimbursement
Medicare and Medicaid rate changes, Medicare Part D and PBM contracts are key risks; Medicare Part D was 29.6% and Medicaid 11.4% of Q3 2026 revenue.
Clinical staffing
Recruitment and retention of nurses, pharmacists, therapists and caregivers is a stated risk; personal care demand continues to outstrip the company's ability to provide it.
Indebtedness
Long-term debt net of current portion was $2,146,779 thousand at September 30, 2026.

What leadership says

“We could do $400 million of EBITDA in M&A tomorrow. If we wanted to.”

Jon Rousseau, Chairman, President and CEO · Q3 2026 earnings call, October 30, 2026

“the household name and national brand for primary care out in the community”

Jon Rousseau, Chairman, President and CEO · Q3 2026 earnings call, October 30, 2026

“the highest service levels in the industry and the best cost per fill”

Jon Rousseau, Chairman, President and CEO · Q3 2026 earnings call, on Home and Community Pharmacy, October 30, 2026

“the annualized revenue contribution from the 2026 launches is tracking ahead”

Jennifer Phipps, CFO · Q3 2026 earnings call, October 30, 2026

Where a supplier can help

AI for documentation and medication review
Tied to the technology and AI investment: tools that automate clinical documentation, medication review and hiring fit projects the company expects to pay back in 2027.
Clinical recruiting and retention
Tied to the clinical staffing challenge: recruiting, scheduling and workforce platforms for nurses, pharmacists and caregivers.
Pharmacy cost per fill
Tied to the Home and Community Pharmacy goal of the best cost per fill and the IRA headwind: automation, logistics and intake systems that cut dispensing cost.
Acquisition integration
Tied to the M&A playbook: IT and back-office integration services for acquired home health and hospice branches.
Value-based care infrastructure
Tied to the REACH ACO and primary care priority: population health analytics, care coordination and virtual care tools.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like BrightSpring Health Services?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about BrightSpring Health Services

What does BrightSpring Health Services do?

BrightSpring provides pharmacy services (specialty, infusion and home and community pharmacy) and provider services (home health, hospice, primary care, rehab and personal care) to complex Senior and Specialty patients in home and community settings across the US.

What is BrightSpring's revenue?

FY2025 revenue was $12.9 billion, up 28.2%, with Adjusted EBITDA of $617.6 million. 2026 guidance is $15,900 million to $16,125 million of revenue.

How many employees does BrightSpring have?

It had over 23,500 full-time equivalent employees at December 31, 2025, and approximately 12,700 clinical providers and pharmacists as of Q3 2026.

Who leads BrightSpring?

Jon Rousseau is Chairman, President and CEO; Jennifer Phipps is CFO.

What is BrightSpring's strategy?

Grow specialty and infusion pharmacy, build home-based primary care and value-based care, integrate pharmacy and provider services for the same patients, and add tuck-in acquisitions while reducing leverage.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)